NICE recommends Merck ’s Erbitux to treat patients with metastatic colorectal cancer

The UK National Institute for Health and Care Excellence (NICE) has issued a positive final appraisal determination (FAD) for Merck ’s Erbitux (cetuximab) to treat patients with RAS wild-type metastatic colorectal cancer (mCRC).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news